ATE383769T1 - Inhibitoren des transkriptionsfaktors nf-kappa b - Google Patents

Inhibitoren des transkriptionsfaktors nf-kappa b

Info

Publication number
ATE383769T1
ATE383769T1 AT99930345T AT99930345T ATE383769T1 AT E383769 T1 ATE383769 T1 AT E383769T1 AT 99930345 T AT99930345 T AT 99930345T AT 99930345 T AT99930345 T AT 99930345T AT E383769 T1 ATE383769 T1 AT E383769T1
Authority
AT
Austria
Prior art keywords
kappa
inhibitors
transcription factor
transcription
factor
Prior art date
Application number
AT99930345T
Other languages
English (en)
Inventor
James Callahan
Marie Chabot-Fletcher
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE383769T1 publication Critical patent/ATE383769T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99930345T 1998-06-19 1999-06-18 Inhibitoren des transkriptionsfaktors nf-kappa b ATE383769T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8982798P 1998-06-19 1998-06-19

Publications (1)

Publication Number Publication Date
ATE383769T1 true ATE383769T1 (de) 2008-02-15

Family

ID=22219773

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99930345T ATE383769T1 (de) 1998-06-19 1999-06-18 Inhibitoren des transkriptionsfaktors nf-kappa b

Country Status (21)

Country Link
US (3) US6492425B1 (de)
EP (1) EP1085848B1 (de)
JP (1) JP2002518307A (de)
KR (1) KR20010052991A (de)
CN (1) CN1311629A (de)
AR (1) AR019692A1 (de)
AT (1) ATE383769T1 (de)
AU (1) AU4690099A (de)
BR (1) BR9911152A (de)
CA (1) CA2335294A1 (de)
CO (1) CO5021213A1 (de)
CZ (1) CZ20004761A3 (de)
DE (1) DE69937997T2 (de)
ES (1) ES2299251T3 (de)
HU (1) HUP0102782A3 (de)
IL (1) IL140328A0 (de)
NO (1) NO20006451L (de)
PL (1) PL348969A1 (de)
TR (1) TR200003781T2 (de)
WO (1) WO1999065449A2 (de)
ZA (1) ZA200007447B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE497001T1 (de) 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
WO1999058674A2 (en) 1998-05-14 1999-11-18 Immunex Corporation Method of inhibiting osteoclast activity
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
GB9930616D0 (en) * 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
EP1134221A1 (de) * 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituierte beta-Carboline als lkB-Kinasehemmer
FR2813315B1 (fr) * 2000-08-23 2002-10-18 Genfit S A Procede d'identification de substances utiles pour le traitement de l'inflammation mettant en oeuvre l'element de reponse du recepteur ror du gene ikbalpha
WO2002049632A1 (en) * 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
DE60217532T8 (de) 2001-11-07 2008-02-07 Millennium Pharmaceuticals, Inc., Cambridge Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
WO2003103658A1 (ja) * 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 免疫関連プロテインキナーゼ阻害剤
CA2488342A1 (en) * 2002-06-05 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Therapeutic drug for diabetes
AU2003242103A1 (en) * 2002-06-06 2003-12-22 Institute Of Medicinal Molecular Design, Inc Antiallergic agents
US7626042B2 (en) 2002-06-06 2009-12-01 Institute Of Medicinal Molecular Design, Inc. O-substituted hydroxyaryl derivatives
EA010835B1 (ru) * 2002-06-10 2008-12-30 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения рака
EP1535609A4 (de) * 2002-06-10 2009-01-07 Inst Med Molecular Design Inc Nf-kb-aktivierungshemmer
US20060035944A1 (en) * 2002-06-11 2006-02-16 Susumu Muto Remedies for neurodegenerative diseases
US7324455B2 (en) 2003-03-14 2008-01-29 International Business Machines Corporation Transfer of error-analysis and statistical data in a fibre channel input/output system
US20050256132A1 (en) * 2003-04-30 2005-11-17 Wyeth Use of ER selective NF-kB inhibitors for the treatment of sepsis
WO2004098510A2 (en) * 2003-04-30 2004-11-18 Beth Israel Deaconess Medical Center Cystic fibrosis therapy
US20050004164A1 (en) * 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
US7981915B2 (en) * 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
NZ545447A (en) * 2003-07-23 2010-03-26 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
US7425580B2 (en) 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
WO2006117660A2 (en) * 2005-05-04 2006-11-09 Clio Pharmaceutical Corporation Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins
CN100418532C (zh) * 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
WO2009054439A1 (ja) 2007-10-23 2009-04-30 Institute Of Medicinal Molecular Design, Inc. Pai-1産生抑制剤
CN101918017B (zh) * 2007-10-25 2013-07-31 植物药学公司 Phy906用于治疗炎性肠病和/或肠易激综合征的用途
US8609730B2 (en) * 2008-01-08 2013-12-17 The Trustees Of The University Of Pennsylvania Rel inhibitors and methods of use thereof
US20090264514A1 (en) * 2008-04-18 2009-10-22 The Research Foundation Of State University Of New York SPHINGOMYELIN SYNTHASE 2 (SMS2) DEFICIENCY ATTENUATES NFkB ACTIVATION, A POTENTIAL ANTI-ATHEROGENIC PROPERTY
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
US9969677B2 (en) 2010-12-22 2018-05-15 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase modulators and uses thereof
TWI492920B (zh) * 2012-04-18 2015-07-21 Nat Defense Medical Ct 水楊酸苯胺衍生小分子之醫藥組合物及其製備與醫藥用途
WO2014113467A1 (en) * 2013-01-15 2014-07-24 Board Of Regents, The University Of Texas System Stat3 inhibitor
WO2015027120A1 (en) 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
JP2017511340A (ja) 2014-03-31 2017-04-20 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク ヒストンアセチルトランスフェラーゼ活性剤及びその使用
ES2661000T3 (es) 2014-09-12 2018-03-27 Antibiotx A/S Uso antibacteriano de salicilanilidas halogenadas
CN105797154B (zh) * 2014-12-31 2020-03-10 中国科学院上海生命科学研究院 软骨干细胞的分离及其应用
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
WO2017122209A2 (en) * 2016-01-12 2017-07-20 Yeda Research And Development Co. Ltd. NF-kappaB INHIBITORS
AU2017224122B2 (en) 2016-02-26 2024-04-11 The Board Of Regents Of The University Of Texas System Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
GB201604484D0 (en) * 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
BR112019019519A2 (pt) 2017-03-21 2020-04-22 Novalead Pharma Inc agente terapêutico para a inibição de fosfodiesterase e seus distúrbios relacionados
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
EP4061351A4 (de) * 2019-11-18 2023-12-20 The Regents of the University of California Doppelte androgenrezeptor/akr1c3-inhibitoren

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1079177A (en) * 1963-06-11 1967-08-16 Stecker Internat S P A Improvements in pesticide composition for destroying internal worm parasites in animals
GB1079178A (en) * 1966-07-27 1967-08-16 Stecker Internat S P A Improvements in pesticide compositions for destroying internal worm parasites in animals
US4742083A (en) * 1983-08-24 1988-05-03 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4803279A (en) 1985-05-23 1989-02-07 Smithkline Beckman Corporation 1.4-dihydro-4-pyridyl-substituted imidazo (2,1-b) thiazoles and the corresponding thiazines.
AU8495091A (en) * 1990-08-21 1992-03-17 Upjohn Company, The Bisphosphonic acid derivatives as anti-arthritic agents
EP0584238A1 (de) * 1991-05-17 1994-03-02 Chiron Corporation Inhibitor von nf-kb transkriptions-aktivator und seine verwendungen
US5466715A (en) * 1991-12-31 1995-11-14 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
DE4200534A1 (de) * 1992-01-11 1993-07-15 Henkel Kgaa Neue n-benzyl-4-aminophenole und deren verwendung als entwicklerkomponente in oxidationshaarfaerbemitteln
DE69432985D1 (de) * 1993-06-15 2003-09-04 Australian Nat University Acto Synergistische anthelmintische zusammensetzungen gegen fasciola hepatica und andere fascola spezien
EP1005347A4 (de) * 1997-08-06 2002-08-28 Smithkline Beecham Corp Antagonisten der rezeptoren der monozyten makrophagen zur verwendung im behandlung kardiovaskuläre erkrankungen

Also Published As

Publication number Publication date
TR200003781T2 (tr) 2001-07-23
US20060035979A1 (en) 2006-02-16
IL140328A0 (en) 2002-02-10
ES2299251T3 (es) 2008-05-16
BR9911152A (pt) 2001-03-06
CO5021213A1 (es) 2001-03-27
AU4690099A (en) 2000-01-05
ZA200007447B (en) 2002-02-13
DE69937997T2 (de) 2009-02-19
KR20010052991A (ko) 2001-06-25
WO1999065449A8 (en) 2001-03-08
EP1085848A2 (de) 2001-03-28
WO1999065449A3 (en) 2000-03-30
NO20006451D0 (no) 2000-12-18
US6492425B1 (en) 2002-12-10
EP1085848B1 (de) 2008-01-16
EP1085848A4 (de) 2004-09-08
CZ20004761A3 (cs) 2001-08-15
AR019692A1 (es) 2002-03-13
HUP0102782A3 (en) 2002-12-28
JP2002518307A (ja) 2002-06-25
DE69937997D1 (de) 2008-03-06
CA2335294A1 (en) 1999-12-23
HUP0102782A2 (hu) 2001-12-28
WO1999065449A2 (en) 1999-12-23
PL348969A1 (en) 2002-06-17
US20030092771A1 (en) 2003-05-15
NO20006451L (no) 2000-12-18
CN1311629A (zh) 2001-09-05

Similar Documents

Publication Publication Date Title
EP1085848A4 (de) Inhibitoren des transkriptionsfaktors nf-kappa b
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
ID19198A (id) Inhibitor metaloprotease heterosiklik
NO20012980D0 (no) Proteaseinhibitorer
ID18416A (id) Inhibitor metaloprotease diheterosiklik
DE69724809D1 (de) Refluxinhibitoren
IS5574A (is) Útskiptir Xa-þáttar oxóasaheterósýklýl-tálmar
ATE410439T1 (de) Caspase inhibitoren
ATE245142T1 (de) No-synthase inhibitoren
FI963597L (fi) Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no) Fibronectin-adhesjonsinhibitorer
FI972160A0 (fi) Matriisimetalloproteaasi-inhibiittorit
ATE460424T1 (de) Factor viia inhibitore
ID18141A (id) Inhibitor metaloprotease 1,3-diheterosiklik
NO20012960D0 (no) Farnesylproteintransferase-inhibitorer
NO20024201D0 (no) Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on og anvendelse derav for hemning av hormonsensitiv lipase
ID18417A (id) Inhibitor ditentat metaloprotease
DE69526475D1 (de) 5-Alphareduktase-Inhibitoren
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
FI964781L (fi) Uusia elastaasi-inhibiittoreita
NO20010085D0 (no) Angiogeneseinhibitorer
MA24877A1 (fr) INHIBITEURS DE PROTéASES
NO990116D0 (no) Korrosjonsinhibering
NO993161L (no) Cyklooksygenaseinhibitor
DE69720957T2 (de) Ace-hemmer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties